Ankylosing Spondylitis Is Associated with Increased Prevalence of Left Ventricular Hypertrophy

Helga Midtbø, Eva Gerds, Inger Jorid Berg, Silvia Rollefstad, Roland Jonsson, and Anne Grete Semb

ABSTRACT. Objective. Ankylosing spondylitis (AS) is associated with increased risk for cardiovascular disease (CVD). Left ventricular (LV) hypertrophy is a strong precursor for clinical CVD. The aim of our study was to assess whether having AS was associated with increased prevalence of LV hypertrophy.

Methods. Clinical and echocardiographic data from 139 AS patients and 126 age- and sex-matched controls was used. LV mass was calculated according to guidelines and indexed to height2.7. LV hypertrophy was considered present if LV mass index was >49.2 g/m2.7 in men and >46.7 g/m2.7 in women.

Results. Patients with AS were on average 49 ± 12 years old, and 60% were men. The prevalence of hypertension (HTN; 35% vs 41%) and diabetes (5% vs 2%) was similar among patients and controls, while patients with AS had higher serum C-reactive protein level (CRP; p < 0.001). The prevalence of LV hypertrophy was higher in patients with AS compared to controls (15% vs 6%, p = 0.01). In multivariable logistic regression analysis, having AS was associated with OR 6.3 (95% CI 2.1–19.3, p = 0.001) of having LV hypertrophy independent of the presence of HTN, diabetes, and obesity. In multivariable linear regression analyses, having AS was also associated with higher LV mass (β0.15, p = 0.007) after adjusting for CVD risk factors including sex, body mass index, systolic blood pressure, diabetes, and serum CRP (multiple R2 = 0.41, p < 0.001).

Conclusion. Having AS was associated with increased prevalence of LV hypertrophy independent of CVD risk factors. This finding strengthens the indication for thorough CVD risk assessment in patients with AS. (J Rheumatol First Release June 1 2018; doi:10.3899/jrheum.171124)

Key Indexing Terms:
ANKYLOSING SPONDYLITIS
LEFT VENTRICULAR HYPERTROPHY
ECHOCARDIOGRAPHY
HYPERTENSION
a cross-sectional study, where patients were recruited from the Oslo area in Norway and the gross majority of the patients included were white. The study started in 2008 and data collection was completed in 2010, including control subjects. Of 257 patients invited to participate, 159 agreed (response rate 62%). Of those, 17 patients were excluded because of established CVD (defined as previous cardiac surgery/intervention, myocardial infarction, angina pectoris, transitory ischemic attack, cerebral infarction, and intermittent claudication). Additional 3 patients were excluded because of insufficient quality of the echocardiographic images. Thus, for our present analyses, a total of 139 patients with AS were included.

**Control subjects.** Control subjects without inflammatory joint disease, stratified for age, sex, and residential area to the participating patients with AS, were randomly selected by Statistics Norway. Of the 329 invited control subjects, 132 (40%) agreed to participate. Six control subjects were excluded because of established CVD, leaving a control group of 126 subjects. All patients and controls signed an informed consent according to the Declaration of Helsinki, and the study protocol was approved by the South Eastern Norwegian Regional Committee for Medical and Health Research Ethics (approval no. S-02059).

**AS disease characteristics.** Duration of disease was defined from the onset of symptoms as previously recommended16. HLA-B27 status was obtained from medical records (available in 116 patients with AS). Disease activity was calculated by the Bath Ankylosing Disease Activity Index (BASDAI)17 and the Ankylosing Spondylitis Disease Activity Score (ASDAS)–C-reactive protein (CRP)18. Physical function was assessed by the Bath Ankylosing Spondylitis Functional Index (BASFI)19.

**Health status.** Self-reported information about the participants’ medical history, smoking status, and current medical therapy were collected by a standardized questionnaire. The information was later quality-assured by the consultant cardiologist (AGS) during the consultation. Obesity was defined as body mass index (BMI) ≥ 30 kg/m².

**Laboratory measurements.** Total cholesterol and CRP were analyzed in fasting blood samples by the COBAS 6000 machine (Roche Diagnostics). Erythrocyte sedimentation rate (ESR) was analyzed by the Westergen method.

**Blood pressure.** Brachial blood pressure was measured in accordance with the European Society of Hypertension guidelines using an OMRON M7 apparatus20. The average of the 2 last measurements was taken as the clinic blood pressure in the individual subject. Hypertension (HTN) was defined as use of antihypertensive medication, a history of HTN, or elevated blood pressure (systolic office blood pressure ≥ 140 mmHg and/or diastolic office blood pressure ≥ 90 mmHg) at the clinical visit.

**Echocardiography.** The transthoracic echocardiograms were recorded during the period between 2008 and 2010 using a Vivid 7 (General Electric Vingmed Ultrasound) scanner and a standardized protocol. All the echocardiographic images were stored electronically and forwarded for analysis at the Echocardiography Core Laboratory at Haukeland University Hospital, Bergen, Norway. The echocardiograms were analyzed by the same reader (HM) on digital workstations equipped with Image Arena software version 4.1 (TomTec Imaging Systems GmbH), and proofread for quality assurance by the same highly experienced reader (EG). Quantitative echocardiography in the study was performed following the joint guidelines from the European Association of Cardiovascular Imaging and American Society of Echo-cardiography21. LV mass was indexed for height², and LV hypertrophy was considered present if LV mass index was > 49.2 g/m²² in men and > 46.7 g/m²² in women². Relative wall thickness was defined as twice LV posterior wall thickness/internal LV diameter ratio in end-diastole and considered high if it was ≥ 0.43². LV geometry was defined from LV mass index and relative wall thickness in combination, and considered normal if both measures were normal; as concentric remodeling if high relative wall thickness but normal LV mass index was present; as eccentric LV hypertrophy if high LV mass index but normal relative wall thickness was present; and as concentric LV hypertrophy if both LV mass index and relative wall thickness were high². LV systolic function was assessed from ejection fraction calculated by the biplane method of disks²³. LV diastolic function was assessed from LV filling as the ratio of the peak mitral early (E) and late (A) velocities measured at the tips of mitral leaflets (E/A ratio), and LV filling pressure by the ratio of E and the early septal mitral annulus velocity (e’)²⁴. Aortic valve regurgitation was graded by color Doppler²⁵.

**Statistics.** The statistical analyses were done using IBM SPSS statistics version 23.0 (IBM). Categorical variables are presented as n (%). Normally distributed continuous data are expressed as mean and SD, and non-normally distributed continuous data (ESR and CRP) as median and interquartile range. Non-normally distributed variables were log-transformed before inclusion in univariable and multivariable analyses. Comparisons between groups were performed by the chi-squared test and the 2-sample Student t test as appropriate. Univariable associations were assessed with linear regression models, and standardized β coefficients and p values were reported. Multivariable linear regression analyses were run with an enter method and co-linearity tools. Results were reported as multiple R² for the overall models, and standardized β coefficients for the individual variables. Results of logistic regression were reported as OR and 95% CI for the individual variables. A 2-tailed p value of < 0.05 was considered statistically significant in all analyses.

**RESULTS**

**Clinical characteristics.** The patients with AS were less obese than controls (p = 0.03), while the prevalence of HTN, diabetes, and current smoking did not differ (Table 1). Further, patients with AS had higher CRP and ESR levels, and used more prednisolone and nonsteroidal antiinflammatory drugs (NSAID) than did the controls (p < 0.05, Table 1). The mean disease activity in patients with AS was moderate to high according to BASDAI and ASDAS, but the functional capacity judged by the BASFI score was on average good.

**LV hypertrophy, mass, and geometry.** Patients with AS had higher prevalence of LV hypertrophy than controls (15% vs 6%; p = 0.01; Table 2). In particular, patients with AS had higher prevalence of eccentric LV hypertrophy, while control subjects had higher prevalence of concentric remodeling (Figure 1). Of note, the prevalence of aortic and mitral regurgitation did not differ between the groups, and none had more than mild to moderate insufficiencies (Table 2). Further, patients with AS had lower LV ejection fraction compared to controls (p = 0.006), but the diastolic function assessed by LV filling and e’ was similar (Table 2). In multivariable logistic regression analysis, having AS was associated with a 6.3-fold higher OR (95% CI 2.1–19.3, p = 0.001) of having LV hypertrophy after adjusting for sex, HTN, diabetes, and obesity (Table 3). When evaluating patients with AS separately, AS disease characteristics such as disease duration and antirheumatic medication were not associated with LV hypertrophy (Table 3). The presence of HTN, obesity, diabetes, and male sex emerged as the main covariates of LV hypertrophy in patients with AS.

In subsequent analyses focusing on LV mass, having AS (β 0.15, p = 0.007) was associated with higher LV mass after adjusting for BMI, sex, systolic blood pressure, age, diabetes, and serum CRP levels (Table 4). There was a univariable association between higher CRP levels and LV mass in the total study population (Table 4), that became nonsignificant after adjusting for other CV risk factors (Table 4). There were no significant associations between AS disease characteristics...
and LV mass in univariable analyses among patients with AS, except for a weak association of higher LV mass with use of NSAID (β = 0.18, p = 0.04). However, this association became nonsignificant after adjusting for CV risk factors in another multivariable model (data not shown).

Although having AS was not associated with increased LV relative wall thickness, the duration of having AS was associated with higher LV relative wall thickness (β = 0.24, p = 0.005) in univariable analysis. But after adjusting for age in a multivariable model, this association became statistically nonsignificant (data not shown).

**DISCUSSION**

To our knowledge, our present study is the first to demonstrate that patients with AS have an increased prevalence of LV hypertrophy, reflecting subclinical CVD. Of note, having AS was associated with the presence of LV hypertrophy and higher LV mass independent of CV risk factors. Further, AS disease activity and use of antirheumatic medication was not associated with LV hypertrophy, indicating that having AS is associated with LV hypertrophy *per se*.

Altered LV structure has previously been reported in other chronic inflammatory disorders, such as rheumatoid arthritis (RA) and gout (in particular when CV risk factors such as HTN, obesity, and diabetes are present); this was also the case for patients with AS in our study. In previous studies in patients with AS, the prevalence of HTN was reported to be higher, and the prevalence of diabetes was comparable to that of the general population. In contrast, in our current study, the prevalence of HTN was similar between patients with AS and controls, while the controls had more obesity. The high prevalence of concentric remodeling seen among control subjects in our study is likely to be a result of the high prevalence of obesity. In obesity, the visceral and pericardial fat tissue produces angiotensinogen, adipokinins, proinflammatory cytokines, and mineralocorticoid-releasing factors, leading to chronic CV inflammation and subsequent myocardial fibrosis and increased LV wall thickness. On
Table 2. Echocardiographic characteristics in patients with AS and controls. Values are mean ± SD or n (%).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>AS, n = 139</th>
<th>Controls, n = 126</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>LV structure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LV septum thickness at end-diastole, cm</td>
<td>0.98 ± 0.22</td>
<td>0.95 ± 0.18</td>
<td>0.26</td>
</tr>
<tr>
<td>LV posterior wall thickness at end-diastole, cm</td>
<td>0.86 ± 0.16</td>
<td>0.85 ± 0.16</td>
<td>0.35</td>
</tr>
<tr>
<td>LV diameter at end-diastole, cm</td>
<td>4.9 ± 0.6</td>
<td>4.8 ± 0.5</td>
<td>0.06</td>
</tr>
<tr>
<td>LV mass, g</td>
<td>164 ± 49</td>
<td>152 ± 49</td>
<td>0.05</td>
</tr>
<tr>
<td>LV mass index, g/m².7</td>
<td>36.6 ± 9.8</td>
<td>34.3 ± 10.0</td>
<td>0.06</td>
</tr>
<tr>
<td>Relative wall thickness, ratio</td>
<td>0.35 ± 0.08</td>
<td>0.35 ± 0.08</td>
<td>0.95</td>
</tr>
<tr>
<td>Concentric LV geometry</td>
<td>18 (13)</td>
<td>27 (21)</td>
<td>0.07</td>
</tr>
<tr>
<td>LV hypertrophy</td>
<td>21 (15)</td>
<td>7 (6)</td>
<td>0.01</td>
</tr>
<tr>
<td>LV function</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E/A ratio</td>
<td>1.3 ± 0.4</td>
<td>1.4 ± 0.5</td>
<td>0.75</td>
</tr>
<tr>
<td>E/e’</td>
<td>8.4 ± 3.1</td>
<td>8.4 ± 2.8</td>
<td>0.89</td>
</tr>
<tr>
<td>Ejection fraction, %</td>
<td>66 ± 6</td>
<td>68 ± 5</td>
<td>0.006</td>
</tr>
<tr>
<td>Valvular function</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aortic regurgitation, any</td>
<td>19 (14)</td>
<td>21 (17)</td>
<td>0.50</td>
</tr>
<tr>
<td>Moderate aortic regurgitation</td>
<td>5 (4)</td>
<td>5 (4)</td>
<td>0.87</td>
</tr>
<tr>
<td>Mitral regurgitation, any</td>
<td>63 (45)</td>
<td>61 (48)</td>
<td>0.62</td>
</tr>
</tbody>
</table>

AS: ankylosing spondylitis; LV: left ventricular; E/A: early/atrial transmitral peak velocities; E/e’: early peak blood velocity/early diastolic tissue velocity at septal border of mitral annulus.

Figure 1. LV geometry in patients with AS and controls. AS: ankylosing spondylitis; LV: left ventricular.
the other hand, having AS is associated with increased risk for aortic valve regurgitation. Presence of aortic regurgitation has been associated with larger LV cavity dimensions and eccentric LV hypertrophy, and could represent a pathophysiological mechanism of LV hypertrophy in patients with AS when the aortic valve regurgitation is of mild severity. In our present study population, the vast majority of aortic valve regurgitation was of mild severity (grade 1), and presence of aortic valve regurgitation was therefore not identified as a covariable of LV hypertrophy.

In line with previous studies in patients with AS, the prevalence of aortic regurgitation was 14% in our present study. However, the prevalence of aortic regurgitation in the control subjects was 17%, which was higher than in the earlier studies. In the Framingham Offspring Study, the prevalence of aortic regurgitation was 13.0% in men and 8.5% in women, with increasing prevalence with age in both sexes. The higher prevalence of aortic regurgitation among our controls could not only represent statistical variance in a relatively small study sample, but also characteristics such as a high prevalence of male sex and CV risk factors in our control group.

The traditional understanding that LV hypertrophy is mainly related to hemodynamic factors such as blood pressure has recently been challenged. Although reduction of LV mass during systematic antihypertensive treatment has been demonstrated in randomized clinical trials, previous publications from real-world practice have shown that persistent LV hypertrophy is common despite modern antihypertensive treatment. These results suggest that nonhemodynamic factors such as inflammation are important in the pathogenesis of LV hypertrophy. The present results are in line with these findings. In AS, we have previously demonstrated that higher disease activity by ASDAS was associated with increased arterial stiffness, and that a history of uveitis was associated with presence of HTN and atherosclerosis. Also in RA, disease activity has been associated with higher risk of subclinical and clinical CVD. However, accelerated atherosclerosis was not found in AS patients with low disease activity in a previous metaanalysis. Recently, in a small study of 14 patients with AS using cardiac magnetic resonance...
imaging (MRI), it was found that increased myocardial extracellular volume, a marker of diffuse interstitial fibrosis, was associated with higher inflammatory markers (CRP and ESR)\textsuperscript{43}. Presence of excessive myocardial fibrosis contributes to LV hypertrophy\textsuperscript{39}, providing a possible underlying mechanism for our finding of increased prevalence of LV hypertrophy in AS. However, in our present study, neither AS disease activity nor uveitis was associated with presence of LV hypertrophy. AS disease duration was also not associated with LV hypertrophy, possibly reflecting that development of LV hypertrophy with increasing age is closely dependent on presence of concomitant CV risk factors\textsuperscript{44}.

A valid question would be whether LV mass could be reduced by immunomodulation therapy in patients with AS. To the best of our knowledge, this has not been tested in patients with AS. However, a small echocardiographic study of 28 patients with RA demonstrated a significant reduction of LV mass index after 6 months of treatment with a tumor necrosis factor α (TNF-α) inhibitor\textsuperscript{45}. In another small cardiac MRI study in 20 patients with RA, LV mass index was significantly reduced with use of the interleukin 6 inhibitor tocilizumab\textsuperscript{46}. In line with these findings, induction of LV hypertrophy by angiotensin II has also been shown to be attenuated in TNF-α knockout mice compared to wild-type mice\textsuperscript{47}.

These results suggest an emerging role of inflammation in the development of LV hypertrophy in inflammatory diseases like AS. However, the effects of immunomodulation therapy and AS disease activity in relation to LV structure and hypertrophy need to be further investigated in a prospective study.

Some important study limitations should be mentioned. The cross-sectional study design is unsuited to demonstrate any causality between having AS and presence of LV hypertrophy. The low participation rate among invited controls may also have introduced a selection bias. The study strengths are the use of a core laboratory for analysis of echocardiography as recommended for echocardiographic studies\textsuperscript{48}, and prognostically validated cutoff values for identification of LV hypertrophy\textsuperscript{8,9}.

Having AS was associated with higher prevalence of LV hypertrophy, reflecting subclinical CVD, independent of CV risk factors. The results could help to explain the increased risk of CVD in patients with AS and strengthens the indication for thorough CV risk assessment in patient groups with inflammatory disorders. Of concern is the fact that only 53% of hypertensive AS patients were using antihypertensive treatment in our study, pointing to the unmet potential of LV hypertrophy in AS by following guideline recommendations for CV disease prevention\textsuperscript{20}. Echocardiography should be included in routine CV risk assessment in patients with AS, given that unmanaged LV hypertrophy is associated with poor prognosis\textsuperscript{8,22}.

REFERENCES

10. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.